Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 159   

Articles published

MRK 59.99 +0.47 (0.79%)
price chart
Merck Announces Positive Phase III Results For Odanacatib; Drug's Safety ...
Merck & Co., Inc. (MRK) announced yesterday, positive results from Phase III trials of its drug odanacatib, used to treat osteoporosis in postmenopausal women.
Stock Update: Merck & Co Inc (NYSE:MRK) � Merck Announces Data from ...  Jutia Group
Merck Says Odanacatib Meets Primary Endpoints Phase 3 Fracture Outcomes ...  NASDAQ
Related articles »  
3 Reasons Merck & Co., Inc.'s Stock Could Fall
If you were lucky enough to time your purchase of Merck (NYSE: MRK ) during the heights of the Great Recession, your investment has probably seen a return of 100% or greater.
Related articles »  
Is it Time to Buy Merck & Co., Inc.'s Stock?
Investors in pharmaceutical giant Merck (NYSE: MRK ) have to be liking what they've witnessed in recent years as Merck's stock has vaulted to its highest levels since prior to the Great Recession. However, back Merck's chart out to a 15-year view and ...
Related articles »  
Merck & Co., Inc. Wins First Stage of the PD-1 Race
Merck (NYSE: MRK ) has won the race to get the first immunotherapy drug that blocks the PD-1 pathway on the U.S. market. Today, the FDA approved pembrolizumab, which will go by the brand name Keytruda, for patients with advanced or unresectable ...
Merck Beats Bristol-Myers In Breakthrough Cancer Drug Race  Bidness ETC
FDA Approves Merck's New-Wave Cancer Drug  Wall Street Journal
Related articles »  
Uptrend Stocks: Merck & Co. Inc. (NYSE:MRK), MDU Resources Group Inc ...
Merck & Co. Inc. (NYSE:MRK) [Trend Analysis] released data from the pivotal Phase 3 fracture outcomes study for odanacatib, the firm's investigational once-weekly cathepsin K inhibitor, in postmenopausal women with osteoporosis.
Related articles »  
Is Merck & Co., Inc. A Leader In A Red Hot Market?
Merck & Co., Inc. (NYSE: MRK) stock has been on a steady incline for the most part since the 2009 bottom. With the stock now challenging 2007�2008 highs, will the underlying fundamentals be enough to incite an upside breakout?
Merck & Co., Inc. to Issue Quarterly Dividend of $0.44 on October 7th (MRK)  sleekmoney
BMO Capital Markets Raises Merck & Co. Price Target to $64.00 (MRK)  WKRB News
Related articles »  
Bristol-Myers, Merck In Patent Battle To Take Lead In Immunotherapy Market
Merck & Co., Inc. (MRK) has been sued by Bristol-Myers Squibb Co (BMY) and Ono Pharmaceutical Co., Ltd. (Japan) (OPHLY) for patent infringement of Bristol-Myers' novel PD-1 inhibitor, Optivo.
FDA OKs Merck drug, 1st in new cancer drug class  Casper Star-Tribune Online
Related articles »  
Merck & Co. Inc. (MRK) Tops DJIA Gainers for September 3
The Dow closed at 17,078.30 on Wednesday, which is a 0.06% move from yesterday's close. Merck & Co. Inc. led all gainers with a 1.15% jump.
Related articles »  
3 Reasons Merck & Co., Inc.'s Stock Could Rise
For investors lucky enough to have jumped into Merck (NYSE: MRK ) in 2009 at the tail end of the Great Recession you've seen an appreciation in your shares of near 100%.
Related articles »  
Big Pharma: $100 Billion In Future Sales Expected
Of these multi-billion dollar sales, more than one-third will be from the oncology segment, accredited to PD-1 antibodies led by Bristol-Myers Squibb Co (BMY) and Merck & Co., Inc. (MRK). Other leading therapy areas include metabolic and autoimmune ...